Takeda Shores Up Pipeline Ahead Of Actos Patent Expiry
This article was originally published in PharmAsia News
Executive Summary
Takeda plans to file six new chemical entities by 2010 as part of an effort to shore up its portfolio ahead of patent expiry for its biggest product, diabetes drug Actos (pioglitazone), in 2011